Helps you feel fuller longer and supports GLP-1 to help bridge the daily fiber gap
Preclinical and clinical data support the role of GLP-1RAs in reducing systemic inflammation, improving organ function, and enhancing survival in various sepsis models
CrossRef The GutLiver Axis in Metabolic DysfunctionAssociated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics Shaoliang Zhu, Mengjie Zou, Qijun Wu, Yan Zou, Tingting Tan, Zhangnan Huang, Zheng Gong, Honglin Luo, Xiaofeng Dong The FASEB Journal .2026;[Epub] CrossRef Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos Current Diabetes Reports .2026;[Epub] CrossRef Association between weekend catch-up sleep and Metabolic dysfunction-associated steatotic liver disease in US adults Jinlong Chen, Wei Wang, Jie He, Xinxin Fang Clinical and Experimental Medicine .2026;[Epub] CrossRef Ginsenoside Rg1 alleviates MASH by targeting GLS2 to enhance PINK1/Parkin-mediated mitophagy and improve mitochondrial function Zhijian Wang, Yinuo Wang, Peiyun Peng, Huating Luo, Liuling Xiao, Wenxiang Huang Biochemical Pharmacology .2026
Prioritise the use of organ-protective medications (GLP-1 RA, SGLT2i, TZD) in those with cardiorenal disease or NASH or at high risk
